Answers are grounded in this paper and cite their sources.
Purpose Despite advances in epidermal growth factor receptor (EGFR)-targeted therapy for non-small cell lung cancer (NSCLC), real-world data on diagnostic and treatment patterns across all disease stages remain limited. This study used the nationwide Korean EGFR Registry to characterize contemporary clinical practice in EGFR-mutant NSCLC. Materials and Methods A total of 1,522 patients with pathologically confirmed EGFR-mutant NSCLC were prospectively enrolled from 40 Korean institutions (June 2022–June 2024). Data on baseline clinical and molecular characteristics, biomarker testing patterns, and treatment for all lines of therapy were collected using standardized electronic case report forms. Results The median age of the study population was 68 years, 59.7% were female, and 64.5% were never-smokers. Stage IV disease accounted for 57.8% of cases. The predominant EGFR mutations were exon 19 deletion (48.6%) and L858R (47.1%). NGS was performed for ~23% of patients. In patients with stage IV disease, third-generation TKI use increased markedly (14.3% in 2022 vs. 91.1% in 2024). Stage III management was notably heterogeneous; definitive concurrent chemoradiotherapy was used in only 15.3% of stage III patients overall, with surgery-based treatment predominating in stage IIIA and systemic therapy accounting for all treatment in stage IIIC. The 3-year overall survival rates were 97.2%, 90.9%, 78.3%, and 58.4% for stages I–IV, respectively. Conclusion This nationwide registry analysis reveals rapid adoption of third-generation TKIs in metastatic EGFR-mutant NSCLC and substantial heterogeneity in stage III disease management. These findings provide clinically meaningful insights into the evolving treatment paradigm of EGFR-mutant NSCLC across disease stages in routine practice.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: